Wyeth Pharmaceuticals (New Jersey)
5 Giralda Farms
Madison
New Jersey
07940
United States
Tel: 973-660-5500 or 800-934-5556
Fax: 973-660-7111
About Wyeth Pharmaceuticals (New Jersey)
At Wyeth we have a vision of leading the way to a healthier world. We've committed ourselves to achieving this vision by making quality, integrity, and excellence the hallmarks of our business. Through recruitment, development, and motivation of the best people, we are continually growing and improving our business. We lead in innovation by linking pharmaceutical, biotechnology, and vaccine technologies.
Headquartered in Madison, New Jersey, Wyeth is one of the largest research-based pharmaceutical and health care products companies in the world. Wyeth is dedicated to solving the world's most critical health problems through research and development, spending approximately $2.1 billion in overall R&D in 2002. With annual sales of nearly $14.6 billion in 2002 and products sold in more than 140 countries, Wyeth is truly a global health care leader.
Our efforts focus on finding and developing new drugs that will enhance the quality of health care worldwide. Our discovery and development process - based on the scientific platforms of small molecules, therapeutic proteins, and vaccines - has led to innovative treatment and prevention strategies for musculoskeletal diseases, bacterial meningitis, hemophilia, and other serious threats to health worldwide.
We are committed to excellence - in the results we achieve and in how we achieve them. We pride ourselves on quality manufacturing; responsible sales, marketing, and licensing alliances; commitment to educational programs and initiatives; and service to health care professionals and patients.
We employ more than 42,000 people worldwide - each one committed to improving the health of people around the world. The diverse and talented people who work at Wyeth bring to the company a full range of talent in research, marketing, sales, and manufacturing. It is our employees who keep us on the cutting edge of innovative discoveries and superior customer service.
Lead the way to a better career at Wyeth. www.wyeth.com/careers
Last Updated: 11-14-03
33 articles about Wyeth Pharmaceuticals (New Jersey)
-
Deceptive Trade Suit Against Drug Makers Including Wyeth Pharmaceuticals (New Jersey) Pfizer Inc. and Pharmacia & Upjohn (Merged to form Pharmacia Corp) to Proceed
7/29/2011
-
Wyeth Pharmaceuticals (New Jersey) Initiates Phase II And Pays Ablynx Another Milestone of $4 Million In The Tnf-Alpha Nanobody(R) Collaboration
9/30/2009
-
Wyeth Pharmaceuticals Race Discrimination Ruling Highlights Forced Double Shifts at N.Y. Factory
4/2/2009
-
Cyclogenix Enters Research Collaboration with Wyeth Pharmaceuticals (New Jersey) and Queensland’s IMBcom
2/26/2009
-
Ablynx Reaches Milestone In Tnf-Alpha Nanobody(R) Collaboration As Wyeth Pharmaceuticals (New Jersey) Initiates Phase I
12/10/2008
-
Karo Bio AB and Wyeth Pharmaceuticals (New Jersey) Collaboration - Targets Inflammation
11/20/2008
-
Wyeth and Progenics Pharmaceuticals, Inc. Relistor Misses Goal In Improving Gastrointestinal Function After Surgery
5/22/2008
-
FDA Approves Wyeth Pharmaceuticals (New Jersey)'s PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
3/3/2008
-
Crucell N.V. Announces Vaccine Development Agreement with Wyeth Pharmaceuticals (New Jersey)
3/3/2008
-
Medidata Solutions, Inc.'s Medidata Rave Selected by Wyeth Pharmaceuticals (New Jersey) for Enterprise-Wide EDC Deployment
10/23/2007
-
Wyeth Hot Flashes Drug Succeeds in Trial-Research
10/8/2007
-
Wyeth and Progenics Pharmaceuticals, Inc. Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
8/29/2007
-
Crucell N.V. Announces PER.C6(R) and AdVac(R) Technology License Agreement with Wyeth Pharmaceuticals
7/30/2007
-
Wyeth Announces Results of Highly Successful Implementation of Closed Loop Marketing at 2007 EyeforPharma Sales Force Effectiveness Conference
3/13/2007
-
Decoding Alzheimer's
1/9/2007
-
Catalyst Biosciences, Inc. And Wyeth Pharmaceuticals Sign Two Agreements For Novel Biotherapeutic Platform Of Engineered Proteases
1/8/2007
-
Progenics Pharmaceuticals, Inc. Earns $5 Million From Wyeth For Achieving Methylnaltrexone Milestone
10/25/2006
-
First Prempro Suit Goes To Trial In Ark.T
8/21/2006
-
Wyeth Pharmaceuticals (New Jersey) Release: Desvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement In Symptoms Of Depression In Adult Patients Versus Placebo
5/25/2006
-
Wyeth Pharmaceuticals (New Jersey) Release: New Findings From Two Studies On Lybrel Presented At ACOG
5/9/2006